To correct an error in the previously published article regarding the effects of injectable estradiol on testosterone suppression in transgender and gender-diverse populations, specifically clarifying the percentage of patients achieving testosterone suppression.
Key Findings:
In the corrected article, 21.6% of patients achieved testosterone suppression below 50 ng/dL while maintaining estradiol levels within the recommended range, indicating a lower efficacy than previously stated.
The original statement incorrectly implied a higher rate of testosterone suppression, necessitating a reevaluation of treatment protocols.
Interpretation:
The correction highlights the need for further investigation into the efficacy of estradiol monotherapy in achieving testosterone suppression without the use of antiandrogens, suggesting potential risks and benefits that require careful consideration.
Limitations:
The study does not clarify how the remaining patients achieved testosterone suppression, indicating a gap in understanding.
Further research is needed to understand the implications of estradiol use without antiandrogens, particularly in diverse populations.
Conclusion:
The article has been corrected to provide accurate data on the use of injectable estradiol in the targeted population, emphasizing the need for ongoing research to better understand treatment outcomes.
